Fig. 3.

Comparison of in vivo anti-leukemia activities of tetrandrine citrate and IM against IM-resistant K562 xenografts in nude mice

Tetrandrine citrate or IM was administered at 100 mg/kg body weight orally three times daily (8:00 AM, 2:00 PM, and 8:00 PM) for 10 consecutive days. Effects of IM on the growth of IM-resistant K562 xenografts (a, b), and body weight of tumor-bearing mice; (c, d) Effects of tetrandrine citrate on the growth of IM-resistant K562 xenografts, and body weight of tumor-bearing mice